FluoGuide A/S

Stockholm Stock Exchange FLUO.ST

FluoGuide A/S Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 4.07 M

FluoGuide A/S Net Cash Used Provided By Financing Activities is USD 4.07 M for the year ending December 31, 2023, a 66.67% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

FluoGuide A/S Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 2.44 M, a -68.78% change year over year.
FluoGuide A/S Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD 7.82 M, a 177.96% change year over year.
FluoGuide A/S Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 2.81 M, a 42.13% change year over year.
FluoGuide A/S Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 1.98 M.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Stockholm Stock Exchange: FLUO.ST

FluoGuide A/S

CEO	Mr. Morten Albrechtsen B.B.A., BBA, M.D.
IPO Date	June 17, 2019
Location	Denmark
Headquarters	Ole MaalOees Vej 3
Employees	7
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Medical Instruments Pharmaceuticals

Description

FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.

Key trends

Past 5 years